Microcap Ledger Biodesix Inc $BDSX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Services-Medical Laboratories
- Headquarters
- Louisville, CO
- Fiscal year end
- December 31
- Shares outstanding
- 10,551,118 [10-Q 2026-08-05]
What the company doesAI summary of filing
Biodesix develops and commercializes blood-based diagnostic tests for lung disease and provides diagnostic development services to biopharmaceutical and life sciences companies. The company derives revenue from two sources: Biodesix Lung Diagnostic Testing, which generated $79.2 million in revenue in 2025 from five blood-based tests addressing lung nodule diagnosis and lung cancer treatment guidance and monitoring, and Biodesix Development Services, which generated $9.3 million in revenue in 2025 by providing diagnostic testing services and consulting to biopharmaceutical clients. The company is revenue-generating, with total estimated 2025 revenue of $88.5 million, and sells its diagnostic tests directly to healthcare providers, hospitals, and biopharmaceutical companies. [10-K 2026-02-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $52.42M | −$15.07M | −$11.73M | $30.00M | [10-Q 2026-08-05] |
| FY ended Dec 2025 | $88.50M | −$35.27M | −$23.27M | $18.99M | [10-K 2026-02-26] |
| FY ended Dec 2024 | $71.32M | −$42.93M | −$48.65M | $26.25M | [10-K 2026-02-26] |
- Quarterly cash burn
- −$5.87M
- Cash runway Estimate
- ~15.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-25 | 145,467,295 | [10-Q 2024-11-01] |
| 2025-02-24 | 145,978,410 | [10-K 2025-03-03] |
| 2025-05-07 | 146,563,031 | [10-Q 2025-05-13] |
| 2025-07-31 | 146,633,352 | [10-Q 2025-08-07] |
| 2025-10-28 | 7,955,685 | [10-Q 2025-11-03] |
| 2026-02-20 | 9,858,358 | [10-K 2026-02-26] |
| 2026-04-29 | 10,108,580 | [10-Q 2026-05-04] |
| 2026-07-30 | 10,551,118 | [10-Q 2026-08-05] |
- Shelf registration
- S-3 filed 2026-05-21; declared effective 2026-05-29 [S-3 2026-05-21]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-03-28. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-03-28 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-03-28] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-30 | Patience John | exercise | 1,360 | — | [4 2026-10-02] |
| 2026-08-12 | Schuler Jack W | buy | 15,000 | $24.47 | [4 2026-08-13] |
| 2026-08-11 | Schuler Jack W | buy | 13,700 | $24.01 | [4 2026-08-12] |
| 2026-08-10 | Schuler Jack W | buy | 13,900 | $24.25 | [4 2026-08-12] |
| 2026-06-30 | Patience John | exercise | 1,361 | — | [4 2026-07-02] |
| 2026-03-31 | Patience John | exercise | 1,361 | — | [4 2026-04-02] |
| 2026-02-23 | Pestano Gary Anthony | sell | 556 | $12.78 | [4 2026-02-23] |
| 2026-02-23 | O'Kane Kieran | sell | 535 | $12.78 | [4 2026-02-23] |
| 2026-02-23 | Cowie Robin Harper | sell | 535 | $12.78 | [4 2026-02-23] |
| 2026-02-20 | Pestano Gary Anthony | exercise | 1,528 | — | [4 2026-02-23] |
| 2026-02-20 | O'Kane Kieran | exercise | 1,469 | — | [4 2026-02-23] |
| 2026-02-20 | Cowie Robin Harper | exercise | 1,469 | — | [4 2026-02-23] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Results of operations |
| 2026-06-18 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-01 | 424B3 | Prospectus or prospectus supplement |
| 2026-05-21 | S-3 | Registration statement |
| 2026-05-20 | 8-K | Shareholder vote results |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-08 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-04 | 10-Q | Quarterly report |
| 2026-05-04 | 8-K | Results of operations |
| 2026-04-28 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-04-09 | DEF 14A | Proxy statement |
Alerts for $BDSX
Email me when Biodesix Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.